Inhibition of HSP90 activity in cancer cells results in degradation of client proteins, such as TYK2 and RIPK1, and reduction in NF-κB signaling, STAT3 phosphorylation and ERK activation [55–60], the changes seen in DLBCL cells treated with doxycycline (Figures 1 and 4). This evidence concerns the gene HSP90AA1 and diffuse large B-cell lymphoma.